Patients' Costs Associated With Seeking and Accessing Treatment for Drug-Resistant Tuberculosis in South Africa
Abstract
South Africa is one of the world's 22 high tuberculosis (TB) burden countries, with the second highest number of notified rifampicin-resistant TB (R(R)-TB) and multidrug-resistant TB (MDR-TB) cases.PubMed ID
26614194Language
enISSN
1815-7920ae974a485f413a2113503eed53cd6c53
10.5588/ijtld.15.0341
Scopus Count
Collections
Related articles
- Cost of multi drug resistance tuberculosis in Germany.
- Authors: Diel R, Nienhaus A, Lampenius N, Rüsch-Gerdes S, Richter E
- Issue date: 2014 Nov
- Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
- Authors: Schnippel K, Rosen S, Shearer K, Martinson N, Long L, Sanne I, Variava E
- Issue date: 2013 Jan
- Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
- Authors: Cox H, Ramma L, Wilkinson L, Azevedo V, Sinanovic E
- Issue date: 2015 Oct
- Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
- Authors: Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E
- Issue date: 2018 Feb
- Financial barriers and coping strategies: a qualitative study of accessing multidrug-resistant tuberculosis and tuberculosis care in Yunnan, China.
- Authors: Hutchison C, Khan MS, Yoong J, Lin X, Coker RJ
- Issue date: 2017 Feb 22